Latest News

The Medicines and Healthcare Products Regulatory Agency (MHRA) is advising medical practitioners to make sure patients are informed about the known adverse effects of agonists…

Sugemalimab, also known as(Equijubi), has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat adult patients with “non-small cell lung cancer.”…

The Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized elafibranor (Iqirvo) for the treatment of adult patients suffering from primary biliary cholangitis (PBC), a…

Hympavzi (marstacimab-hncq) was approved by the U.S. Food and Drug Administration for routine prophylactic use in patients aged 12 and up who have hemophilia A…

An adult COVID-19 vaccine (Comirnaty) that targets the KP.2 subvariant has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA). The immune system’s…

Patients who use insulin pumps or continuous glucose monitors (CGMs) are being asked by the Medicines and Healthcare Products Regulatory Agency (MHRA) to promptly report…

Marketing permission for the Healgen Rapid Check COVID-19/Flu A&B Antigen Test was given by the U.S. Food and Drug Administration. The test is approved for…

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved leniolisib phosphate (Joenja) to treat a rare immune disease known as activated phosphoinositide 3-kinase delta…

Steps to maximize the utilization of EU’s specialized resources for expedited evaluations, working together, the European Medicines Agency (EMA) and the European Medicines Regulatory Network…

Cobenfy (xanomeline and trospium chloride) capsules have been approved by the US Food and Drug Administration for oral use in the treatment of adult schizophrenia.…

EMA’s human medicines committee (CHMP) has recommended suspending the marketing authorisation for the sickle cell disease medicine Oxbryta (voxelotor); this measure is taken as a…

The Medicines and Healthcare products Regulatory Agency (MHRA) approved the new medicine fruquintinib (Fruzaqla) to care for adult patients who have colorectal cancer that has…

The U.S. Food and Drug Administration approved FluMist for self- or caregiver-administration. FluMist is authorized for the prevention of influenza in those ages 2 to 49 who…

The U.S. Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Niemann-Pick disease, type C (NPC). Miplyffa, in combination with the…

The European Medicines Agency (EMA) has suggested expanding the use of the Imvanex smallpox and mpox vaccine to adolescents between the ages of 12 and…